Literature DB >> 16985939

The androgen-deficient aging male: current treatment options.

J Lisa Tenover.   

Abstract

All delivery forms of testosterone should be equally efficacious in treating the androgen-deficient aging male if adequate serum testosterone levels are obtained. The testosterone preparations available in North America include the oral undecanoate, injectable testosterone esters, the scrotal patch, the nonscrotal transdermal patch, and the transdermal gels. Selection of a specific testosterone preparation for replacement therapy depends on many factors, including the magnitude and pattern of serum testosterone levels produced, side effects of the particular formulation, reversibility if an adverse event should occur, convenience of use, cosmetic issues related to the preparation, and cost. In addition, potential adverse effects of testosterone therapy applicable to all forms of testosterone delivery, such as fluid retention, gynecomastia, polycythemia, worsening of sleep apnea, change in cardiovascular-disease risk, or alterations in prostate health, need to be considered both prior to therapy and during treatment monitoring.

Entities:  

Year:  2003        PMID: 16985939      PMCID: PMC1502321     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  17 in total

1.  Effect of testosterone treatment on bone mineral density in men over 65 years of age.

Authors:  P J Snyder; H Peachey; P Hannoush; J A Berlin; L Loh; J H Holmes; A Dlewati; J Staley; J Santanna; S C Kapoor; M F Attie; J G Haddad; B L Strom
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

2.  Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.

Authors:  S Khosla; L J Melton; E J Atkinson; W M O'Fallon
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

3.  Pharmacokinetics and pharmacodynamics of testosterone pellets in man.

Authors:  D J Handelsman; A J Conway; L M Boylan
Journal:  J Clin Endocrinol Metab       Date:  1990-07       Impact factor: 5.958

4.  Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study.

Authors:  N E Skakkebaek; J Bancroft; D W Davidson; P Warner
Journal:  Clin Endocrinol (Oxf)       Date:  1981-01       Impact factor: 3.478

5.  Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate.

Authors:  M Schulte-Beerbühl; E Nieschlag
Journal:  Fertil Steril       Date:  1980-02       Impact factor: 7.329

6.  Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.

Authors:  R S Swerdloff; C Wang; G Cunningham; A Dobs; A Iranmanesh; A M Matsumoto; P J Snyder; T Weber; J Longstreth; N Berman
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

7.  Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.

Authors:  A S Dobs; A W Meikle; S Arver; S W Sanders; K E Caramelli; N A Mazer
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

8.  Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep.

Authors:  A M Matsumoto; R E Sandblom; R B Schoene; K A Lee; E C Giblin; D J Pierson; W J Bremner
Journal:  Clin Endocrinol (Oxf)       Date:  1985-06       Impact factor: 3.478

9.  High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered.

Authors:  K E Friedl; C J Hannan; R E Jones; S R Plymate
Journal:  Metabolism       Date:  1990-01       Impact factor: 8.694

10.  Liver damage from long-term methyltestosterone.

Authors:  D Westaby; S J Ogle; F J Paradinas; J B Randell; I M Murray-Lyon
Journal:  Lancet       Date:  1977-08-06       Impact factor: 79.321

View more
  4 in total

Review 1.  Erythrocytosis Following Testosterone Therapy.

Authors:  Samuel J Ohlander; Bibin Varghese; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-05-16

2.  Testosterone replacement in men with andropause: an overview.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

3.  Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen.

Authors:  Alexander W Pastuszak; Lissette P Gomez; Jason M Scovell; Mohit Khera; Dolores J Lamb; Larry I Lipshultz
Journal:  Sex Med       Date:  2015-08-12       Impact factor: 2.491

4.  Effects of Eurycoma longifolia on Testosterone Level and Bone Structure in an Aged Orchidectomised Rat Model.

Authors:  Abdul Shukor Tajul Ariff; Ima Nirwana Soelaiman; J Pramanik; Ahmad Nazrun Shuid
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-26       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.